Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New antiplatelet agents].

J H Beer1

  • 1Departement Innere Medizin, Kantonsspital Baden.

Praxis
|July 20, 1999
PubMed
Summary
This summary is machine-generated.

Aspirin remains a cornerstone for preventing and treating cardiovascular diseases. Future antithrombotic therapies will likely involve combinations of aspirin with other platelet inhibitors and novel antagonists.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro fertilization exacerbates stroke size and neurological disability in wildtype mice.

International journal of cardiology·2021
Same author

Tumour Necrosis Factor-α Inhibition Improves Stroke Outcome in a Mouse Model of Rheumatoid Arthritis.

Scientific reports·2019
Same author

Frequency of use and acceptability of clinical prediction rules for pulmonary embolism among Swiss general internal medicine residents.

Thrombosis research·2017
Same author

Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Omega-3 fatty acids predict recurrent venous thromboembolism or total mortality in elderly patients with acute venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2016
Same author

CardioPulse: Mentoring young physician-scientists. A Position and Practice Guide by a Young MD/PhD and a Department Head.

European heart journal·2016

Area of Science:

  • Cardiovascular medicine
  • Pharmacology
  • Thrombosis research

Context:

  • Aspirin is the established standard for platelet inhibition in cardiovascular disease prophylaxis and treatment.
  • Invasive procedures and new antiplatelet agents are transforming antithrombotic therapy.
  • Future therapeutic strategies are expected to involve further diversification of treatment options.

Purpose:

  • To review the evolving landscape of antithrombotic treatment.
  • To identify key trends in the development and application of platelet inhibitors.
  • To discuss the future directions in cardiovascular disease management.

Summary:

  • The current standard of care for cardiovascular diseases involves aspirin for platelet inhibition.
  • Novel platelet inhibitors and invasive techniques are reshaping antithrombotic strategies.

Related Experiment Videos

  • Three primary trends are emerging: combining aspirin with other inhibitors (ticlopidine, clopidogrel), utilizing new glycoprotein IIb/IIIa antagonists, and combining established inhibitors with novel antagonists.

    • Impact:

    • This review highlights the dynamic nature of antithrombotic therapy.
    • Understanding these trends is crucial for optimizing patient care in cardiovascular medicine.
    • Anticipated diversification in antiplatelet therapies promises improved outcomes in managing thrombotic events.